Novel enzyme-linked immunosorbent assay for determination of fluvastatin in plasma at picogram level

For the first time, an enzyme-linked immunosorbent assay (ELISA) has been developed and validated for the determination of fluvastatin (FLV) in plasma samples at picogram level. The assay employed a polyclonal antibody that specifically recognizes FLV with high affinity, and FLV conjugate of bovine serum albumin (FLV–BSA) immobilized onto microplate wells as a solid-phase. The assay involved a competitive binding reaction between FLV, in plasma sample, and the immobilized FLV–BSA for the binding sites on a limited amount of the anti-FLV antibody. The bound anti-FLV antibody was quantified with horseradish peroxidase-labeled second anti-rabbit IgG antibody (HRP-IgG) and 3,3′,5,5′-tetramethylbenzidine (TMB) as a substrate for the peroxidase enzyme. The concentration of FLV in the sample was quantified by its ability to inhibit the binding of the anti-FLV antibody to the immobilized FLV–BSA and subsequently the color intensity in the assay wells. The conditions for the proposed ELISA were investigated and the optimum conditions were employed in the determination of FLV in plasma samples. The assay limit of detection was 10 pg mL−1 and the effective working range at relative standard deviations (RSD) of ≤5% was 20–1000 pg mL−1. Analytical recovery of FLV from spiked plasma was 97.1–102.7 ± 2.85–6.25%. The precision of the assay was satisfactory; RSD was 2.46–5.37 and 3.19–6.64% for the intra- and inter-assay precision, respectively. The analytical procedure is convenient, and one can analyze ∼200 samples per working day, facilitating the processing of large-number batch of samples. The proposed ELISA has a great value in routine analysis of FLV for its therapeutic monitoring and pharmacokinetic studies.